Henry Schein, Inc. Q2 2026 Earnings Call Summary
Henry Schein reported Q2 2026 progress including faster internal local-currency sales growth, driven by dental merchandise market-share gains and higher technology platform share. The company raised full-year 2026 sales growth guidance to 4.5% to 5.5% and expects $125 million operating income improvement run rate by end-2026. Restructuring expenses were $29 million.
How this was made
The 30-second read
Why it matters
Traders can update models around 2026 sales growth, operating income improvement milestones, and the earnings bridge (notably lower remeasurement gains). The call also highlights an AI-enabled technology launch and a shift to an integrated operating approach.
Market read
The most tradable elements are the raised 2026 sales growth range, the quantified operating income improvement run-rate, and the reduced 2026 remeasurement gains that create a reported-EPS headwind.
What to watch
The guidance assumes no further remeasurement gains and stable FX; any FX move or additional remeasurement items could change the earnings bridge versus what the call implies.
Background
This is a summary of Henry Schein’s Q2 2026 earnings call, focusing on strategic drivers, restructuring, and updated 2026 guidance.
Ticker impact
Henry Schein raised full-year 2026 sales growth guidance to 4.5% to 5.5% and outlined restructuring, remeasurement, and operating income improvement targets.
Bias modestly positive for the next few sessions, with EPS sensitivity to the reduced 2026 remeasurement gains.
The article provides multiple forward-looking, decision-relevant datapoints: raised sales guidance, operating income run-rate targets, and a quantified reduction in remeasurement gains that creates a reported-EPS headwind.
Market effects
Signals continued shift toward high-margin technology and specialty mix in dental distribution, reinforcing read-through for practice-management software demand.
Notes divergence in implant performance between Europe and the U.S., which may affect regional dental product demand expectations.
Global outsourcing and integrated operating model changes could influence cost structure expectations across healthcare services supply chains.
Counterpoint
The raised sales guidance may not translate to reported EPS strength because 2026 remeasurement gains are cut to $11 million from $38 million in 2025, and restructuring expenses rose to $29 million in Q2.
Key entities
- public_companyHenry Schein, Inc.
Dental and healthcare technology/distribution company providing Q2 2026 call updates, including raised 2026 sales guidance and operating income improvement targets.
- product_platformHenry Schein One (Dentrix Ascend migration)
Technology platform gaining share of wallet as customers migrate to cloud-based Dentrix Ascend, with stated monthly revenue per customer.
- product_launchAI-enabled MCP layer
Upcoming technology launch described as enabling practices to query their own data for revenue and operational opportunities.
